1 Department of Internal Medicine III, Medical Faculty, Aachen University of Technology, D-52057 Aachen, Germany; and 2 Department of Medicine, Division of Gastroenterology and Hepatology, Karolinska Institute, Huddinge University Hospital, S-14186 Stockholm, Sweden
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Hepatic synthesis and plasma
levels of glutathione are markedly decreased in chronic liver
disease. Because glutathione turnover is highest in kidneys, we
examined whether changes in kidney glutathione occur in chronic
cholestasis and whether they are related to kidney dysfunction in liver
disease. Kidney and plasma GSH and GSSG were measured 1) in
bile duct-ligated (BDL) rats; 2) in healthy rats after bile
acid loading to mimic cholestasis; and 3) after irreversible inhibition of glutathione synthetase with buthionine-sulfoximine (BSO),
where glutathione consumption, urinary volume, and sodium excretion
were also estimated. In addition, -glutamylcysteine synthetase
(
-GCS) mRNA, protein, and enzymatic specific activity were measured
in kidney tissue after BDL. After BDL, kidney GSH and GSSG increased
within hours by 67 and 66%, respectively. The increases were not
related to plasma glutathione, which decreased below control values.
Intravenous bile acid loading caused identical increases in GSH and
GSSG as occurred after BDL, when glycine- or taurine-conjugated
dihydroxy bile acids were administered. Glutathione consumption, as
estimated after blocking of de novo synthesis with BSO, was
significantly increased after BDL (127 vs. 44 nmol · g
1 · min
1).
-GCS mRNA and enzymatic specific activity were significantly reduced
5 days after BDL, whereas protein concentrations did not change. The
urinary sodium concentration was 70% lower in BDL than in control
rats. Depletion of renal glutathione normalized sodium excretion by
increasing urinary sodium concentration and urinary volume. The
increase in kidney glutathione after BDL seems to be mediated by an
increase in plasma bile acids and is critically related to sodium
retention. The increase in GSH consumption despite reduced
-GCS
activity indicates a decreased GSH turnover tentatively due to reduced
renal GSH efflux by competition with organic anions at membrane
transport proteins.
bile duct ligation; sodium excretion; glutathione depletion; -glutamylcysteine synthetase
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
GLUTATHIONE
(-glutamyl-cysteinyl-glycine) is a multitasking tripeptide that is
present in every mammalian cell. Highest concentrations are found in
the liver, kidney, and other parenchymal organs. Glutathione
participates in a wide range of redox and conjugation reactions and has
regulatory functions (6, 14, 32). Decreased hepatic output
and plasma concentrations of glutathione are common features of liver
disease in humans (4) and in experimental animals
(29). Decreased glutathione enhances the susceptibility of
the liver to oxidative damage (e.g., acetaminophen toxicity). According to the concept of interorgan transfer of glutathione (7), the kidney content of glutathione depends on the
transfer of glutathione from the liver to the kidney because only the
liver can synthesize the key constituent of glutathione, cysteine. This transfer is of particular importance in the fasting state, when dietary
cysteine is lacking (25, 26). Changes in hepatic and plasma concentrations of glutathione should therefore influence kidney
glutathione. Because kidneys exhibit the highest organ-specific turnover rates for glutathione (17, 26), decreased renal
glutathione content should be expected in chronic liver disease.
However, continuously increasing levels of kidney GSH and GSSG were
found in experimental carbon tetrachloride-induced cirrhosis in rats, and this increase paralleled the deterioration of liver function (29). It is not known whether these changes were
caused by a direct toxic effect of carbon tetrachloride on the kidneys.
Therefore, the following experiments were done to clarify 1)
whether an increase in kidney glutathione occurs in other forms of
chronic liver disease, 2) whether bile acids influence renal
glutathione metabolism, and 3) what impact changes in
glutathione levels have on renal function.
![]() |
METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Surgery and Sampling
Male Wistar rats [220-250 g body wt (BW)] were held in groups of two in Macrolon cages and fed ad libitum with a standard chow (Altromin, Lage, Germany) and free access to water. The animals were randomly assigned to a bile duct ligation (BDL) or sham-operated group. All rats were anesthetized for surgery and blood or tissue sampling with pentobarbital sodium (40 mg/kg body wt ip). The common bile duct was exposed through a 1-cm-long right paramedian incision. In animals designated as BDL, the common bile duct was ligated twice with silk and cut in between. Ligations were positioned 1 cm distal to the duodenum to avoid ligation of parabiliary pancreatic ductuli. No ligation was performed in sham operations. To circumvent postoperative or diurnal variations in kidney glutathione, each BDL group was compared with a sham-operated group. Each group consisted of five animals.Blood for plasma glutathione was drawn rapidly (6-8 ml within 45 s) from the aorta abdominalis under complete anesthesia 15-20 min after injection of pentobarbital sodium. Tissue samples were removed immediately from the cranial half of the left kidney.
Bile Acid-Loading Experiments
Rats were injected into the dorsal penile vein with a crude mixture of primary and secondary bile acids from ox bile (mixed bile acids, tauroglycocholic acid; Sigma, Deisenhofen, Germany) dissolved in Ringer solution containing (in mM) 147 Na+, 4 K+, 2.3 Ca2+, and 155.5 ClKidney GSH and GSSG were determined at 1, 2, 4, 5, 6, 8, and 12 h after injection of 50 mg/kg BW of the bile acid mixture from ox bile and at 5 h after doses of 20, 50, 100, and 200 mg/kg BW, respectively. Control rats were injected with equal volumes of Ringer solution.
To identify the effect of particular bile acids, glycine or taurine amidates of primary and secondary bile acids were injected in doses of 35 µmol/kg BW, which equals the injected amount of total bile acids in the crude ox bile mixture. The bile acids tested were glycocholic (GCA), taurocholic (TCA), glycochenodeoxycholic (GCDCA), taurochenodeoxycholic (TCDCA), glycodeoxycholic (GDCA), taurodeoxycholic (TDCA), and taurolithocholic acid (TLCA), all from Sigma in the highest purity available (98-99%). Kidney GSH and GSSG were determined 4 h after injection.
Glutathione Consumption/Depletion
Glutathione consumption was assessed by irreversible inhibition of glutathione synthetase (22) using DL-buthionine-[S,R]-sulfoximine (BSO; Sigma). Five days after BDL or sham operation, animals received a single intraperitoneal dose of 2 mmol BSO/kg BW. The concentrations of renal and hepatic glutathione were determined at 15, 30, 60, and 180 min after injection.To assess the metabolic effect of glutathione depletion on bile acid metabolism and kidney function, urine was collected for 24 h before (on day 4 after BDL or sham operation) and after glutathione depletion by BSO (on day 5). For this experiment, two doses of 2 mmol/kg BSO were injected intraperitoneally at 8:00 AM and 8:00 PM on day 5 after surgery. Because the effect of BSO on kidney GSH subsides between 10 and 25 h (12), two injections are mandatory to get low GSH levels throughout the sampling period. Two additional groups after BDL or sham operation received equal volumes of Ringer solution intraperitoneally and served as controls.
All studies were performed in accordance with required standards of the local animal welfare committee.
Analytic Procedures
Glutathione.
GSH and GSSG levels were determined according to Griffith
(11). GSH reacts nonenzymatically with DTNB to yield GSSG
and 2-nitro-5-thiobenzoic acid (TNB). GSSG is then reduced
enzymatically by glutathione reductase using NADPH as a coenzyme to
regenerate GSH, which reacts again ("catalytic assay"). The
formation of TNB is followed spectrophotometrically. GSSG is determined
after incubation of samples with 2-vinylpyridine, which derivatizes GSH. To prevent the rapid breakdown of GSH and GSSG by -glutamyl transpeptidase (
-GT), it was important to chill the samples in an
ice-cold water bath immediately after dissection (28).
Kidney specimens were then rapidly homogenized in 5 ml ice-cold 5%
5-sulfosalicylic acid using an Ultraturrax blender (Jahnke & Kunkel,
Staufen, Germany). Despite cooling, 5-10% of plasma GSH is lost
every 5 min. Thus plasma samples were stabilized exactly 4 min after
vein puncture by adding 10% 5-sulfosalicylic acid.
Bile acids. Materials, procedures, and equipment for the analysis of bile acid profiles in plasma and urine by gas chromatography-mass spectrometry were the same as described previously (19). In short, Sep-Pak C18 cartridges (Waters, Milford, MA) were used for the quantitative extraction of bile acids from urine and from 1 ml of plasma, the latter diluted 10-fold with 0.5 M triethylammonium sulfate, pH 7.4, and heated for 10 min to 65°C to diminish protein adsorption. Separation into different groups of conjugates was then performed by anion-exchange chromatography on Lipidex-DEAP (Packard-Becker, Groningen, The Netherlands) after the addition of cholyl [14C]glycine (Amersham, Buckinghamshire, UK) as an internal standard for the monitoring of recovery and group separation. The following fractions were eluted from Lipidex-DEAP: unconjugated bile acids, glycine- or taurine-otherwise unconjugated bile acids; glycine- or taurine-conjugated bile acid glucuronides; and glycine- or taurine-conjugated bile acid sulfates. The glycine and taurine moieties were hydrolyzed with cholylglycine hydrolase for 24 h at 37°C. Bile acid glucuronides and sulfates, respectively, were then hydrolyzed with the digestive juice of Helix pomatia (L'Industrie Biologique Francaise, Clichy, France) or solvolyzed with trifluoroacetic acid in water-free tetrahydrofuran, both for 1 h at 45°C. Finally, bile acids were converted to volatile methyl ester trimethylsilyl ether derivatives for gas chromatography-mass spectrometry analysis. Aliquots of samples before and after separation on Lipidex-DEAP were analyzed by fast-atom bombardment-mass spectrometry for deprotonated M-1 ions to obtain information about occurrence, successful separation, and hydrolysis of bile acid conjugates.
-Glutamylcysteine Synthetase
Northern blot analysis.
RNA was isolated from whole kidney by standard phenol chloroform
extraction procedures (5). Total mRNA (10 µg) was
analyzed as previously described (9, 33) by Northern
blotting with specific and constitutively expressed cDNA probes of
GAPDH and rat -glutamylcysteine synthetase (
-GCS) heavy chain,
kindly provided by Dr. D. Eaton (University of Washington, Seattle,
WA). Specific mRNA levels were detected after exposure of membranes to
a PhosphorImager screen (Molecular Dynamics, Sunnyvale, CA) and
quantified using ImageQuant software (Bio-Rad).
Western blot analysis.
Preparation of kidney cytosol for analysis of protein mass were
performed as previously described (8). After determination that the linear range was 25-200 µg, similar amounts of protein (75 µg) were separated by SDS-PAGE and probed after transfer to blotting membranes to anti--GCS peptide antiserum, kindly provided by Dr. D. Dickinson (University of Alabama at Birmingham, Birmingham, AL). Immune complexes were detected using an ECL Western blotting kit
(Amercontrols, Little Chalfont, UK). Immunoreactive bands obtained by
autoradiography were quantified by laser densitometry and ImageQuant software.
Activity.
The enzymatic specific activity of -GCS was measured in cytosolic
preparations of kidney tissue. The reaction mixtures contained 0.1 M
Tris · HCl buffer [(in mM) 150 KCl, 10 L-glutamate, 10 L-
-aminobutyrate, 20 MgCl2, 2 Na2EDTA, 0.2 NADH, and 5 Na2ATP]. In a coupled enzyme procedure with lactate
dehydrogenase and pyruvate kinase in the presence of 2 mM
phosphoenolpyruvate, ADP formation was measured spectrophotometrically from the decrease in NADH (31).
-GT
Recoveries
The recoveries of 125 µmol GSSG or 250 µmol GSH, added immediately before kidney tissue homogenization, were 96.6 ± 6.1%. The homogenization technique used was the same for all samples from BDL or sham-operated rats. No excess GSSG formation could be detected when GSH was added. The addition of bile acids (0.1-0.5 mM) also did not affect recoveries.Statistics
Values are expressed as means ± SD. Analysis of variance was used to calculate differences between the sample means. When relevant, statistical tests between the groups were done using Scheffé's test. P < 0.05 was considered significant for rejecting the hypothesis of equal expected means. ![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Kidney Glutathione After BDL
Kidney GSH and GSSG in sham-operated control rats at t = 0 h were 2.86 ± 0.24 and 0.12 ± 0.02 µmol/g wet wt (WW), respectively, and did not differ significantly from these values at 1, 3, 6, or 24 h and 5, 8, 15, 23, or 38 days.Three hours after BDL, a significant increase in GSH to 3.48 ± 0.22 µmol/g WW (+34% compared with 2.60 ± 0.26 µmol/g WW in sham-operated controls, P < 0.01) was detected,
reaching a maximum of 4.84 ± 0.51 µmol/g WW after 24 h
(+67% compared with 2.89 ± 0.27 µmol/g WW in sham-operated
controls P < 0.001). Thereafter, no further increase
was seen (Fig. 1). The increases were
smaller on days 15 and 23 (+52%) and at the end
of the observation period on day 38 (+49%).
|
GSSG also increased significantly 1 h after BDL to 0.16 ± 0.01 µmol/g WW (+24% compared with 0.12 ± 0.01 in sham-operated controls; P < 0.01). GSSG went up to 52-62% above controls between 3 h and day 8, with no statistical difference between the groups. Later on, GSSG increased further to 81 (day 15), 108 (day 23), and 123% (day 38) above the respective controls.
Plasma Glutathione After BDL
GSH and GSSG concentrations in plasma from abdominal aorta of sham-operated controls were 10.0 ± 1.30 and 0.75 ± 0.28 µM, respectively, at t = 0 h. Compared with these values, the maximum decrease in GSH (In contrast, the plasma GSH concentration increased 6 h
after BDL by 18% and was normalized after 24 h (Fig.
2). Comparisons between
sham-operated and BDL rats revealed significant differences (P < 0.05) after 3 h (+31%), 6 h (+48%),
and 5 days (+14%). After 8 days, GSH tended to be lower compared with
sham-operated rats (14%; not significant). Fifteen days after BDL,
the arterial GSH concentration was reduced by 41% (P < 0.05), 45% after 23 days, and 51% at the end of the observation
period (P < 0.01).
|
In BDL rats, arterial GSSG increased by 39 and 62% after 3 and 6 h, respectively (Fig. 2). These increases were significantly different (P < 0.05) compared with sham-operated controls. After 1, 8, and 15 days, no increase was detected. After 23 and 38 days, GSSG was 27 (not signifcant) and 44% (P < 0.05) lower than in controls, respectively.
Bile Acid Profiles
Plasma bile acids and urinary excretion of bile acids increased ~25- and 350-fold, respectively, after BDL compared with sham-operated controls (Table 1). In BDL rats, 95% of plasma and 90% of urinary bile acids were glycine or taurine conjugates. Minor amounts, between 1.4 and 6.4%, of glucuronides and sulfates were found in plasma and urine. The prevalence of these conjugates was confirmed by fast-atom bombardment-mass spectrometry. The spectra that were dominated by deprotonated M-1 ions at mass-to-charge ratios (m/z) of 498 and 514, indicating taurine-conjugated di- and trihydroxy bile acids, also showed ions at m/z of 578 and 594, indicating taurine-conjugated diol and triol sulfates, and at m/z of 674 and 690, indicating the respective glucuronides.
|
Ions indicative of other forms of conjugate were not recorded. After glutathione depletion, the urinary excretion of glucuronides and sulfated bile acids decreased by 29 and 32%, respectively, whereas the excretion rate of unconjugated bile acids increased. These changes were significant (P < 0.05). Plasma bile acids after glutathione depletion did not change significantly in BDL or sham-operated rats (Table 1).
Bile Acid-Loading Experiments
GSSG and GSH rapidly increased after intravenous bile acid injection, as shown for the single dose of 50 mg/kg BW of a crude mixture of bile acids from ox bile (Fig. 3). The maximum GSH increase (+50%) occurred after 4 and 5 h and the maximum GSSG increase (+31%) after 2-5 h. Higher intravenous doses of bile acids did not cause further increases in kidney GSH and GSSG at 5 h after application, as shown in experiments where bile acid doses of 20-200 mg/kg BW were injected. The GSH increases were +26 and +44% after bile acid doses of 20 and 50 mg/kg BW, respectively; thereafter, no significant further increase was observed. The GSSG increase was maximal after a dose of 20 mg/kg BW, and there was no significant further increase with higher doses (Fig. 4).
|
|
The effects of single bile acids are shown in Fig.
5. The amidates of cholic acid, GCA and
TCA, had no effect on GSH but caused a 31 and 26% increase,
respectively, in kidney GSSG (P < 0.01). Conjugates of
deoxycholic acid increased both GSH by 42% (P < 0.01 for GDCA, P < 0.001 for TDCA) and GSSG by 63 and 68%,
respectively (P < 0.001). Conjugates of
chenodeoxycholic acid, GCDCA and TCDCA, caused GSH increases of 31 and
57% and GSSG increases of 49 and 36%, respectively. The taurine
conjugate of lithocholic acid, TCA, had no effect on GSH or GSSG.
|
Glutathione Consumption
Kidney glutathione was determined before and at 15, 30, 60, and 180 min after an intraperitoneal injection of BSO that was administered on day 5 after BDL or sham operation. Kidney glutathione was 5.00 ± 0.66 µmol/g WW in animals after BDL, which was 73% higher than in sham-operated controls. GSH rapidly decreased to 1.3 ± 0.4 µmol/g in both groups within 30 min after BSO application. The initial glutathione consumption was 127 nmol · min
|
Metabolic Effects of Glutathione Depletion on Kidney Function
The effects of BDL on urinary volume and urinary sodium are shown in Fig. 7. Five days after BDL, urinary volume (54 ± 9 ml · kg
|
After glutathione depletion with BSO, urinary volume further increased
to 79 ± 9 ml · kg1 · day
1
(P < 0.01) in BDL rats and, to a lesser extent, in
sham-operated controls (40 ± 3 ml · kg
1 · day
1;
P < 0.05). The urinary sodium concentration after BSO
increased to 100 ± 15 mmol/l in BDL rats (P < 0.01), resulting in a normalization of sodium excretion to 7.8 ± 0.6 mmol · kg
1 · day
1,
which was equal to control values after BSO (8.1 ± 1.2 mmol · kg
1 · day
1).
-GCS
|
The effect of BDL on protein mass is shown in Fig.
9. No significant changes were observed 1 and 5 days after BDL.
|
The enzymatic specific activity of -GCS in kidney tissue of
sham-operated animals was 546 ± 180 nmol · g
1 · min
1.
One and five days after BDL,
-GCS activity decreased significantly to 283 ± 116 (
48%) and 315 ± 57 (
42%)
nmol · g
1 · min
1,
respectively (Fig. 10).
|
-GT
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cholestasis has a strong impact on renal glutathione metabolism. We found that kidney GSH and GSSG rapidly increased after BDL. These changes already occurred within 6 h after BDL and largely persisted until the end of the observation period of 38 days. At this time, complete secondary biliary cirrhosis with ascites is anticipated with decreased liver and plasma glutathione (30).
Elevated kidney glutathione in chronic liver disease was first described in carbon tetrachloride-induced cirrhosis in rats (29). In that model, kidney glutathione increased by 13 and 44% after 15 and 20 wk of treatment, respectively, when complete cirrhosis had developed. The reproducibility of these changes in our study with chronic BDL cholestasis makes direct toxic effects of carbon tetrachloride on the kidneys unlikely.
The physiological hepatic turnover of GSH and GSSG in the adult rat is
characterized by a transport rate into bile of 14.8 ± 1.1 and
2.3 ± 0.2 nmol · min1 · 100 g
1 (17). In cholestasis in general, an
increased sinusoidal hepatic efflux of the tripeptide occurs. After
BDL, the canalicular block also results in an increased junctional
permeability, allowing biliary glutathione to reflux from bile into plasma.
Kidney glutathione is de novo synthesized in the cytosol of each cell
(6). The constituent amino acids are mainly derived from
the degradation of glutathione at the external surface of the luminal
and basolateral membranes of the proximal tubule by the activity of
-GT and dipeptidase (1). As increased availability of glutathione is able to raise the level in the kidney
(32), changes due to cholestasis might therefore be
secondary to elevated plasma glutathione that might also be degraded
more slowly, by inhibition of
-GT activity when amidated bile acids
reach levels as occurred in our study (2).
However, we did not find larger amounts of glutathione in arterial plasma after BDL. In fact, only modest amounts of excess GSH and GSSG were detected in the first 6 h after BDL, and control values were reestablished after 24 h, indicating a downregulation of hepatic glutathione synthesis. Thus the observed rapid increase in plasma glutathione does not explain the lasting changes in kidney glutathione after BDL.
The increase in kidney glutathione was also too rapid to be explained by severe liver dysfunction. Therefore, we speculated that biliary compounds could induce increases in kidney glutathione. These rise rapidly in plasma of rats after BDL. Our hypothesis that bile acids were responsible for the observed changes was confirmed in bile acid-loading experiments. The injection of a crude bile acid mixture resulted in a rapid increase in glutathione identical to that observed after BDL. Bile acid-loading experiments using individual bile acids revealed significant GSH increases after all glycine or taurine conjugates tested, with the exception of taurolithocholic acid, which is a nonrodent compound. GSH increased significantly as well but only after the injection of the conjugates of chenodeoxy and deoxycholic acids. The injection of cholic acid conjugates did not elevate GSH, which is probably due to the higher hepatocellular uptake, thus higher plasma clearance, of these compounds that are most abundant in noncholestatic rodents (15).
The observed increase in kidney glutathione could result from increased
synthesis through stimulation of -GCS, decreased catabolism,
decreased consumption, or diminished turnover by hindered cellular
export. Increased synthesis was ruled out by showing that mRNA
expression and enzymatic specific activity of
-GCS were
significantly reduced 5 days after BDL. Protein concentrations estimated by Western blot analyis tended to decrease, but this did not
reach statistical significance. Decreased catabolism was unlikely by
measuring equal
-GT activities in kidneys of rats with and without
BDL. Finally, we found an increased glutathione consumption after de
novo synthesis was blocked. Thus the increase in kidney glutathione is
probably due to diminished cellular export of the unchanged tripeptide
GSH. This is supported by the following observations.
In cholestasis, renal membrane transport proteins are regulated in a
manner that the excretion of biliary compounds such as bilirubin and
bile acid conjugates is facilitated (18). The main
transporter for these compounds is multidrug resistance-associated protein 2 (MRP2), which is also responsible for the excretion of GSH
(18). However, the upregulation of MRP2 in cholestasis is
obviously not sufficient to export both biliary compounds and glutathione. GSH synthesis is reduced by nonallosteric feedback inhibition of GSH that competes with the substrate at the
L-glutamate binding site of -GCS (13). This
feedback inhibition was obviously very effective. One would have
expected that the oxidative damage that occurs in proximal kidney
tubules under cholestasis (3) should actually stimulate
glutathione synthesis (16).
In the healthy kidney, GSH is continuously exported from kidney cells
and cleaved by -GT, and there is a reuptake of constituent amino
acids into the cells for resynthesis of GSH (1). This cycle is thought to protect the membranes from oxidative damage. Oxidative stress leads to an increase in the cellular redox state that
is reflected by the GSSG/GSH ratio (4.6 ± 0.6% of kidney glutathione is in the oxidized form in control animals). A normal GSSG/GSH ratio is critical for the determination of protein structure, regulation of enzyme activity, and regulation and binding of
transcriptional factors (6, 14). To restore a normal
GSSG/GSH ratio, excess GSSG is either exported from the cell or
intracellular GSH increases (6, 27). In our experiments,
kidney tissue GSSG increased as soon as 1 h after BDL. This
increase was immediately followed by a pronounced GSH increase. Thus
the GSSG/GSH ratio was not different or even lower in BDL compared with
sham-operated rats and increased only at the end of the observation period.
We also gained information about the urinary excretion of bile acid conjugates related to glutathione metabolism. After BDL, the amount of sulfated bile acids in urine increased ~50-fold. As glutathione is a key source for sulfhydryl groups, the increased glutathione consumption after BDL may be related to increased sulfation of bile acids (10). The decreased excretion of sulfated bile acid after glutathione depletion supports this assumption. We also found a significantly reduced excretion of bile acid glucuronides under this condition, which is in accordance with decreased activity of the bile acid-transporting organic anion transporter 1, which is glutathione driven (14, 34).
Finally, we observed changes in the sodium balance. After glutathione depletion in BDL rats, sodium excretion increased and hyperdiuresis was augmented. This may be related to the action of nitric oxide for the following reasons. Similar changes in renal function were observed after inhibition of nitric oxide synthetase in cirrhotic rats (20), and it has been shown that glutathione depletion inhibits nitric oxide production by reducing inducible nitric oxide synthetase gene expression (24). Interestingly, bile acids induce nitric oxide production in vascular endothelial cells (23). Thus a speculative sequence leading to sodium retention after BDL would be a bile acid-induced increase in kidney glutathione as a first step. The second step would be increased synthesis of nitric oxide, leading to a reduction of renal perfusion pressure and sodium retention.
In conclusion, the increase in kidney glutathione seems to be a common feature in cholestatic liver disease in the rat. Hindered cellular export of glutathione is the likely pathomechanism. Elevated bile acid conjugates trigger these changes. The increase in kidney glutathione is related to sodium retention.
![]() |
ACKNOWLEDGEMENTS |
---|
This study was suppoprted by grants from the Deutsche Forschungsgemeinschaft (A. Geier and C. Gartung) and the Swedish Society of Medicine (H.-U. Marschall).
![]() |
FOOTNOTES |
---|
Address for reprint requests and other correspondence: E. Purucker, Dept. of Internal Medicine III, Medical Faculty, Univ. of Technology, Pauwelsstrasse 30, D-52057 Aachen, Germany (E-mail: epurucker{at}ukaachen.de).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
August 6, 2002;10.1152/ajprenal.00237.2001
Received 30 July 2001; accepted in final form 25 July 2002.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Abbott, WA,
Bridges RJ,
and
Meister A.
Extracellular metabolism of glutathione accounts for its disappearance from the basolateral circulation of the kidney.
J Biol Chem
259:
15393-15400,
1984
2.
Abbott, WA,
and
Meister A.
Modulation of -glutamyl transpeptidase activity by bile acids.
J Biol Chem
258:
619-627,
1983.
3.
Bairaktari, E,
Liamis G,
Tsolas O,
and
Elisaf M.
Partially reversible renal tubular damage in patients with obstructive jaundice.
Hepatology
33:
1365-1369,
2001[ISI][Medline].
4.
Burgunder, JM,
and
Lauterburg BH.
Decreased production of glutathione in patients with cirrhosis.
Eur J Clin Invest
17:
408-414,
1987[ISI][Medline].
5.
Chomczynski, P,
and
Sacchi N.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal Biochem
162:
156-159,
1987[ISI][Medline].
6.
Deneke, SM.
Thiol-based antioxidants.
Curr Top Cell Regul
36:
151-180,
2000[ISI][Medline].
7.
Deneke, SM,
and
Fanburg BL.
Regulation of cellular glutathione.
Am J Physiol Lung Cell Mol Physiol
257:
L163-L173,
1989
8.
Gartung, C,
Schuele S,
Schlosser SF,
and
Boyer JL.
Expression of the rat liver Na+/taurocholate cotransporter is regulated in vivo by retention of biliary constituents but not their depletion.
Hepatology
25:
284-290,
1997[ISI][Medline].
9.
Geier, A,
Dietrich CG,
Lammert F,
Orth T,
Mayet WJ,
Matern S,
and
Gartung C.
Regulation of organic anion transporters in a new rat model of acute and chronic cholangitis resembling human primary sclerosing cholangitis.
J Hepatol
36:
718-724,
2002[ISI][Medline].
10.
Gregus, Z,
White C,
Howell S,
and
Klaassen CD.
Effect of glutathione depletion on sulfate activation and sulfate ester formation in rats.
Biochem Pharmacol
37:
4307-4312,
1988[ISI][Medline].
11.
Griffith, OW.
Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine.
Anal Biochem
106:
207-212,
1980[ISI][Medline].
12.
Griffith, OW.
Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis.
J Biol Chem
257:
13704-13712,
1982
13.
Griffith, OW.
Biologic and pharmacologic regulation of mammalian glutathione synthesis.
Free Radic Biol Med
27:
922-935,
1999[ISI][Medline].
14.
Hammond, CL,
Lee TK,
and
Ballatori N.
Novel role for glutathione in gene expression, cell death, and membrane transport of organic solutes.
J Hepatol
34:
946-954,
2001[ISI][Medline].
15.
Hofmann, AF.
The enterohepatic circulation of bile acids in man.
Clin Gastroenterol
6:
3-24,
1977[ISI][Medline].
16.
Kondo, T,
Higashiyama Y,
Goto S,
Iida T,
Cho S,
Iwanaga M,
Mori K,
Tani M,
and
Urata Y.
Regulation of gamma-glutamylcysteine synthetase expression in response to oxidative stress.
Free Radic Res
31:
325-334,
1999[ISI][Medline].
17.
Lash, LH,
and
Jones DP.
Renal glutathione transport.
J Biol Chem
23:
14508-14514,
1984.
18.
Lee, J,
Azzaroli F,
Wang L,
Soroka CJ,
Gigliozzi A,
Setchell KD,
Kramer W,
and
Boyer JL.
Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat.
Gastroenterology
121:
1473-1484,
2001[ISI][Medline].
19.
Marschall, H-U,
Roeb E,
Yildiz Y,
Busch N,
Nguyen H,
Purucker E,
Thomas HG,
and
Matern S.
Study of human isoursodeoxycholic acid metabolism.
J Hepatol
26:
863-870,
1997[ISI][Medline].
20.
Martin, PY,
Ohara M,
Gines P,
Xu DL,
St. John J,
Niederberger M,
and
Schrier RW.
Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites.
J Clin Invest
101:
235-242,
1998
21.
Meister, A.
Methods for the selective modification of glutathione metabolism and study of glutathione transport.
Methods Enzymol
113:
571-585,
1985[ISI][Medline].
22.
Naftalin, L,
Sexton M,
Whitaker JF,
and
Tacey D.
A routine procedure for estimating serum -glutamyl transpeptidase activity.
Clin Chim Acta
26:
293-296,
1969[ISI][Medline].
23.
Nakajima, T,
Okuda Y,
Chisaki K,
Shin WS,
Iwasawa K,
Morita T,
Matsumoto A,
Suzuki J,
Suzuki S,
Yamada N,
Toyo-Oka T,
Nagai R,
and
Omata M.
Bile acids increase intracellular Ca2+ concentration and nitric oxide production in vascular endothelial cells.
Br J Pharmacol
130:
1457-1467,
2000
24.
Nikulina, MA,
Andersen HU,
Karlsen AE,
Darville MI,
Eizirik DL,
and
Mandrup-Poulsen T.
Glutathione depletion inhibits IL-1-stimulated nitric oxide production by reducing inducible nitric oxide synthase gene expression.
Cytokine
12:
1391-1394,
2000[ISI][Medline].
25.
Ookhtens, M,
and
Kaplowitz N.
Role of the liver in interorgan homeostasis of glutathione and cyst(e)ine.
Semin Liver Dis
18:
313-329,
1998[ISI][Medline].
26.
Potter, DW,
and
Tran T.
Apparent rates of glutathione turnover in rat tissue.
Toxicol Appl Pharmacol
120:
186-192,
1993[ISI][Medline].
27.
Purucker, E,
Egri L,
Hamar H,
Augustin AJ,
and
Lutz J.
Differences in glutathione status and lipid peroxidation of red and white muscles: alterations following ischemia and reperfusion.
Res Exp Med
191:
209-217,
1991[ISI][Medline].
28.
Purucker, E,
and
Wernze H.
Hepatic efflux and renal extraction of plasma-glutathione: marked differences between healthy subjects and the rat.
Klin Wschr
68:
1008-1012,
1990[Medline].
29.
Purucker, E,
Wernze H,
and
Krandik G.
Glutathione in plasma, liver, and kidney in the development of CCl4-induced cirrhosis of the rat.
Res Exp Med
195:
193-200,
1995[ISI][Medline].
30.
Purucker, E,
Winograd R,
Roeb E,
and
Matern S.
Glutathione status in liver and plasma during development of biliary cirrhosis after bile duct ligation.
Res Exp Med
198:
167-174,
1998[ISI][Medline].
31.
Sekura, R,
and
Meister A.
Gamma-glutamylcysteine synthetase. Further purification, "half of the sites" reactivity, subunits, and specificity.
J Biol Chem
252:
2599-2605,
1977[Abstract].
32.
Shan, X,
Aw TY,
and
Jones DP.
Glutathione-dependent protection against oxidative injury.
Pharmacol Ther
47:
61-71,
1990[ISI][Medline].
33.
Tsuboi, S.
Expression of gamma-glutamylcysteine synthetase mRNA in regenerating rat liver.
Biol Pharm Bull
22:
1113-1115,
1999[ISI][Medline].
34.
Van Aubel, RA,
Masereeuw R,
and
Russel FG.
Molecular pharmacology of renal organic anion transporters.
Am J Physiol Renal Physiol
279:
F216-F232,
2000
|
HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Visit Other APS Journals Online |